IBD research alliance combines academic, industry resources

The Icahn School of Medicine at Mount Sinai in New York has formed an inflammatory bowel disease research alliance with Janssen Biotech and Johnson & Johnson Innovation, according to a press release.

Researchers from the Janssen Immunology Therapeutic Area will work with those from Mount Sinai to identify disease triggers and biomarkers for the illness, as well as potential new IBD therapies. The alliance’s primary goal will be to create a Molecular Interaction Network of Disease to develop and test therapeutic hypotheses in vivo and in vitro, according to the release.

Specific terms of the agreement have not been disclosed.

“The collaboration with Mount Sinai underscores a shared commitment to further understand IBD biology and advance patient care through the discovery of novel therapeutic solutions,” Miguel S. Barbosa, PhD, vice president and head of immunology research and scientific partnership strategy at Janssen Research & Development, said in the release. “By bringing together two excellent scientific teams with a shared long-term vision to improve the health of individuals living with IBD, we will harness the joint expertise and capabilities to deepen the scientific understanding of the disease and deliver future innovative medicines and co-diagnostics.”